Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Dr. Regina Graul is the President of Cyclerion Therapeutics Inc, joining the firm since 2023.
What is the price performance of CYCN stock?
The current price of CYCN is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Cyclerion Therapeutics Inc?
Cyclerion Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Cyclerion Therapeutics Inc market cap?
Cyclerion Therapeutics Inc's current market cap is $NaN
Is Cyclerion Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Cyclerion Therapeutics Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell